Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Human Longevity Supports Innovation to Advance Treatment of Cancer, Other Diseases

June 26, 2014 11:10 am | News | Comments

Human Longevity Inc., a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, called on physicians, the insurance industry and political leaders to support promising new avenues of medical discovery on behalf of patients with life-threatening diseases including cancer. Read more...

TOPICS:

MicroRNA Offers Target for Osteoporosis and Bone Metastases Drugs

June 26, 2014 11:04 am | News | Comments

UT Southwestern cancer researchers have identified a promising molecule - miR-34a from a family of small molecules called microRNAs - that blocks bone destruction and, therefore, could provide a potential therapeutic target for osteoporosis and bone metastases of cancer. Read  more...

TOPICS:

G20 World Brain Mapping and Therapeutics Initiative Partners with EU Human Brain Project

June 26, 2014 10:57 am | News | Comments

According to the World Health Organization's large-scale studies, about a third of the adult worldwide population suffer from a mental disorder such as depression, anxiety and schizophrenia, and European Union, China, India, Japan and Australia are not immune from the high cost of healthcare despite having 100% government insurance. Read more...

TOPICS:
Advertisement

Researchers Closer to Helping Millions Battle Lung Cancer

June 26, 2014 10:51 am | News | Comments

Researchers at the University of Louisville, led by Chi Li, assistant professor of medicine, have uncovered a cadre of small molecules that tell certain proteins to kill lung cancer cells and have published their finding in Molecular and Cellular Biology. Read more...

TOPICS:

Abbvie Cites Tax Break as a Shire Deal Motivator

June 26, 2014 10:44 am | by Tom Murphy, AP Business Writer | News | Comments

U.S. drugmaker AbbVie laid out the reasoning behind their unsolicited, cash-and-stock offer, noting a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well. Read more...

TOPICS:

FDA Committee Rejects Cancer Drug Accelerated Approval

June 26, 2014 10:37 am | News | Comments

AstraZeneca announced that the FDA Oncologic Drugs Advisory Committee voted 11 to 2 that current evidence does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer with germline BRCA (gBRCA) mutation, and who are in complete or partial response to platinum-based chemotherapy. Read more...

TOPICS:

Auxilium to Combine with Eye Drug Maker QLT

June 26, 2014 10:27 am | News | Comments

Auxilium Pharmaceuticals Inc. said Thursday that it plans to combine with Canadian eye drug maker QLT Inc. in an all-stock deal worth about $851 million. Read more...                        

TOPICS:

Ampio Reduces Patient Sample Size in Eye Study

June 25, 2014 2:05 pm | News | Comments

Ampio Pharmaceuticals Inc. announced that it has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes Study for the treatment of Diabetic Macular Edema (oral treatment with Optina). Read more...

TOPICS:
Advertisement

Isis Earns $1M from GSK for Advancing Antisense Drug

June 25, 2014 1:58 pm | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $1 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx, an antisense drug, in patients with familial amyloid polyneuropathy (FAP). Read more...

TOPICS:

Eradication of Gut Methane Improves Insulin Sensitivity, Lipid Profiles

June 25, 2014 1:51 pm | News | Comments

Synthetic Biologics Inc., announced that researchers at Cedars-Sinai Medical Center found that eradication of breath methane and reduction of intestinal levels of the most common methanogenic bacterium in the human gut (M. smithii) resulted in improved insulin sensitivity and a reduction in total cholesterol and LDL cholesterol levels in pre-diabetic, obese human subjects. Read more...

TOPICS:

BMS Expands Access to Clinical Trial Data

June 25, 2014 1:40 pm | News | Comments

Bristol-Myers Squibb announced a collaboration with Duke University through its Duke Clinical Research Institute (DCRI) focused on clinical trial transparency that will expand access to a broader set of clinical trial information from in-scope company-sponsored studies. Read more...

TOPICS:

Researchers Link Brain Gene to Kidney Cancer

June 25, 2014 1:32 pm | News | Comments

A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting in Cancer Research. Read more...

TOPICS:

Researcher Charged in HIV Vaccine Fraud Case

June 25, 2014 1:19 pm | by Ryan J. Foley, Associated Press | News | Comments

Responding to a major case of research misconduct, federal prosecutors have taken the rare step of filing charges against a scientist after he admitted falsifying data that led to millions in grants and hopes of a breakthrough in AIDS vaccine research. Read more...

TOPICS:

Court Upholds Shire Vyvanse Patents

June 25, 2014 11:15 am | News | Comments

Shire plc announced that a U.S. District Court for the District of New Jersey judge granted Shire’s summary judgment motion in a patent infringement lawsuit, holding that certain claims of the patents protecting Vyvanse were both infringed and valid. Read more...

TOPICS:

Prosensa Completes Enrollment in Natural History Study of DMD

June 25, 2014 11:06 am | News | Comments

Prosensa Holding N.V. announced the successful completion of enrollment in its prospective Natural History Study designed to increase the understanding of Duchenne muscular dystrophy (DMD). Read more...               

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading